Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Schimmel, Jonathan
PLATINUM, NCT04443608: Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management	Terminated	4	115	US	Patiromer Powder for Oral Suspension [Veltassa], Active drug, Placebo, Inactive substance	Comprehensive Research Associates	Hyperkalemia	03/23	06/23
INDV-6000-401, NCT04995029: Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users	Completed	4	785	Canada, US	Transmucosal Buprenorphine, Extended-release Buprenorphine, RBP-6000, SUBLOCADE	Indivior Inc.	Moderate to Severe Opioid-use Disorder	06/24	06/24
CARPO, NCT04681066: A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS	Active, not recruiting	2	216	US, RoW	CM-4620 Injectable Emulsion or CM-4620-IE, Auxora, Placebo	CalciMedica, Inc.	Acute Pancreatitis, Systemic Inflammatory Response Syndrome	09/24	09/24
Pradhan, Mitali
PLATINUM, NCT04443608: Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management	Terminated	4	115	US	Patiromer Powder for Oral Suspension [Veltassa], Active drug, Placebo, Inactive substance	Comprehensive Research Associates	Hyperkalemia	03/23	06/23
CARPO, NCT04681066: A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS	Active, not recruiting	2	216	US, RoW	CM-4620 Injectable Emulsion or CM-4620-IE, Auxora, Placebo	CalciMedica, Inc.	Acute Pancreatitis, Systemic Inflammatory Response Syndrome	09/24	09/24